IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Has Average Target Price of $727.69 According to Brokerages

by · The Cerbat Gem

IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the fourteen ratings firms that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $721.67.

A number of equities analysts recently commented on IDXX shares. Barclays dropped their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. The Goldman Sachs Group assumed coverage on shares of IDEXX Laboratories in a research report on Friday, October 16th. They set a “buy” rating and a $740.00 price target on the stock. Citigroup increased their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. BTIG Research dropped coverage on IDEXX Laboratories in a research note on Friday. They set a “buy” rating on the stock. Finally, UBS Group decreased their price target on shares of IDEXX Laboratories from $670.00 to $627.00 and set a “neutral” rating for the company in a research report on Tuesday, October 27th.

Read Our Latest Stock Analysis on IDXX

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director owned 9,568 shares in the company, valued at $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in IDEXX Laboratories by 4.6% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock worth $479,844,000 after purchasing an additional 39,700 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in IDEXX Laboratories by 52.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after buying an additional 288,471 shares in the last quarter. Dimensional Fund Advisors LP grew its position in IDEXX Laboratories by 4.3% in the first quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock valued at $322,145,000 after purchasing an additional 23,582 shares in the last quarter. Finally, Alyeska Investment Group L.P. boosted its stake in IDEXX Laboratories by 97.3% in the second quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after buying an additional 197,808 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $551.21 on Friday. The company has a market capitalization of $43.42 billion, a PE ratio of 38.76 and a beta of 1.55. IDEXX Laboratories has a twelve month low of $500.61 and a twelve month high of $769.98. The business’s 50-day moving average price is $534.27 and its 200 day moving average price is $574.09. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. During the same quarter in the prior year, the business posted $3.50 earnings per share. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, research analysts predict that IDEXX Laboratories will post 14.81 earnings per share for the current year.

About IDEXX Laboratories

(Get Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

Recommended Stories